Clinical Trial Update: An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial of atabecestat in asymptomatic individuals at risk for Alzheimer's dementia was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Atabecestat (atabecestat)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Asymptomatic Amyloid-positive | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2020-02-10